• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

Comprehensive Overview of 4-Bromo-2-(difluoromethoxy)phenol (CAS No. 1261495-47-9): Properties, Applications, and Industry Insights

4-Bromo-2-(difluoromethoxy)phenol (CAS No. 1261495-47-9) is a specialized organic compound gaining attention in pharmaceutical and agrochemical research due to its unique structural features. The presence of both bromine and difluoromethoxy groups on the phenolic ring makes it a versatile intermediate for synthesizing bioactive molecules. Researchers are increasingly exploring its potential in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents.

In recent years, the demand for fluorinated compounds like 4-Bromo-2-(difluoromethoxy)phenol has surged, driven by their enhanced metabolic stability and membrane permeability—key properties in modern drug design. The compound's CAS No. 1261495-47-9 frequently appears in patent literature related to anti-inflammatory and antiviral applications, aligning with global health trends. Its molecular weight (239.02 g/mol) and lipophilicity (LogP ≈ 2.8) make it particularly valuable for CNS-targeting therapeutics, a hot topic in neuroscience research.

The synthesis of 4-Bromo-2-(difluoromethoxy)phenol typically involves electrophilic bromination of 2-(difluoromethoxy)phenol, followed by careful purification. Analytical techniques such as HPLC (purity >98%) and NMR spectroscopy (confirming the difluoromethoxy proton absence at δ 4.8-5.2 ppm) are critical for quality control. These protocols address common user queries about compound validation methods in peer-reviewed forums.

From an industrial perspective, CAS 1261495-47-9 exemplifies the growing market for halogenated aromatics, with compound annual growth rates exceeding 6.5% (2020-2025). Environmental considerations have prompted innovations in greener bromination methods—a frequent search topic among synthetic chemists. The compound's thermal stability (decomposition >200°C) also makes it suitable for high-temperature applications in material science.

Regulatory databases classify 4-Bromo-2-(difluoromethoxy)phenol as non-hazardous under standard handling conditions, though proper PPE (nitrile gloves, goggles) is recommended. This safety profile expands its utility in academic labs, where researchers often search for "stable bromophenol derivatives" or "difluoromethoxy building blocks." The compound's crystalline form (white to off-white powder) and solubility profile (soluble in DMSO, ethanol) further enhance its practicality.

Emerging applications include its use in OLED materials, where the difluoromethoxy group improves electron transport properties—a trending subject in materials science publications. Patent analysis reveals increasing citations of CAS 1261495-47-9 in electroluminescent layer formulations, particularly in blue-emitting systems. This aligns with industry demands for energy-efficient display technologies.

For purchasers, key considerations include storage conditions (2-8°C under inert atmosphere) and supplier certifications (ISO 9001 compliance). Analytical certificates should specify residual solvent levels (<0.5% by GC) and heavy metal content (<10 ppm)—details frequently requested in procurement forums. The compound's pricing reflects the technical challenges of difluoromethoxy introduction during synthesis.

Future research directions may explore the compound's role in PROTAC (Proteolysis Targeting Chimera) development, leveraging its bromine atom for linker conjugation. This connects to trending searches about "targeted protein degradation" platforms. Computational studies suggest the 4-Bromo-2-(difluoromethoxy)phenol scaffold could enhance binding to E3 ubiquitin ligases, opening new drug discovery avenues.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)